MedPath

Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST

Phase 3
Conditions
GIST With D842V Mutated PDGFRA Gene
Interventions
Drug: Placebo
Drug: Crenolanib
Registration Number
NCT02847429
Lead Sponsor
Arog Pharmaceuticals, Inc.
Brief Summary

This is a multicenter, randomized, double-blinded, placebo-controlled, trial of oral crenolanib versus oral placebo in combination with best supportive care in subjects with advanced or metastatic GIST with a D842V mutation in the PDGFRA gene. Approximately 120 subjects will be randomized in a 2:1 ratio to receive either crenolanib 100 mg or matching placebo orally (PO) 3 times daily (TID) in combination with best supportive care.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
120
Inclusion Criteria
  1. Histologically or cytologically-confirmed advanced or metastatic GIST with a D842V mutation in the PDGFRA gene as determined by central laboratory testing

  2. Measurable disease as per modified RECIST 1.1

    • A lesion in an area that was previously treated with local therapy (e.g. radiation, surgery, or cryotherapy) can be considered measurable disease as long as there is objective evidence of progression of the lesion prior to randomization

  3. Subjects (male or female) ≥ 18 years of age

  4. Female subjects with reproductive potential must have negative serum or urine pregnancy test

  5. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2

Read More
Exclusion Criteria
  1. Severe liver disease (e.g. cirrhosis, non-alcoholic steatohepatitis, sclerosing cholangitis)
  2. Known, active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)
  3. Female subject who is pregnant or breastfeeding, or planning to become pregnant within 30 days after ending treatment
  4. Systemic anti-cancer treatment (e.g. chemotherapy, tyrosine kinase inhibitors, immunotherapy, or investigational agents) or investigational device within 3 weeks or 5 half-lives (if the drug's half-life in subject is known) prior to randomization, whichever is shorter
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Placebo ArmPlaceboMatching placebo
Crenolanib ArmCrenolanibInvestigational product (crenolanib)
Primary Outcome Measures
NameTimeMethod
Progression-free survival (PFS) will be measured from the date of randomization to the date of the first objective radiological disease progression according to centralized committee assessment using modified RECIST version 1.1 or death.3 years
Secondary Outcome Measures
NameTimeMethod
Overall survival (OS) will be measured from the date of randomization to the date of death from any cause. OS will be estimated using the Kaplan-Meier method.3 years

Trial Locations

Locations (23)

Sarcoma Oncology Center

🇺🇸

Santa Monica, California, United States

Duke Cancer Institute

🇺🇸

Durham, North Carolina, United States

Oregon Health and Science University

🇺🇸

Portland, Oregon, United States

Institut Bergonie

🇫🇷

Bordeaux, France

La Timone University Hospital

🇫🇷

Marseille, France

Centre Hospitalier Universitaire (CHU) de Reims

🇫🇷

Reims, France

Centre Leon Berard

🇫🇷

Lyon, France

HELIOS Klinikum Berlin-Buch

🇩🇪

Berlin, Germany

Universitätsklinikum München

🇩🇪

Munich, Germany

Mannheim University Medical Centre, University of Heidelberg

🇩🇪

Mannheim, Germany

Policlinico S. Orsola-Malpighi

🇮🇹

Bologna, Italy

Istituto Nazionale Tumori

🇮🇹

Milan, Italy

Institut Regina Elena / IFO

🇮🇹

Rome, Italy

Candiolo Cancer Institute - FPO, IRCCS

🇮🇹

Turin, Italy

Vall d'Hebron University Hospital

🇪🇸

Barcelona, Spain

University Hospital The Norwegian Radium Hospital

🇳🇴

Oslo, Norway

M Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology

🇵🇱

Warsaw, Poland

Hospital Virgen del Rocio

🇪🇸

Sevilla, Spain

Hospital Universitario Puerta de Hierro

🇪🇸

Madrid, Spain

MD Anderson Cancer Center

🇺🇸

Houston, Texas, United States

Fundación Instituto Valenciano de Oncología

🇪🇸

Valencia, Spain

University of Miami

🇺🇸

Miami, Florida, United States

Fox Chase Cancer Center

🇺🇸

Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath